Highlights of weekly biotech stock moves

Columbia Laboratories Inc. (NASDAQ:CBRX) was off $0.09 to $3.14 last week after FDA accepted for review an NDA for Prochieve vaginal progesterone gel to reduce the risk of preterm birth in women with short urterine cervical length in the mid-trimester of pregnancy. The PDUFA date is Feb. 26, 2012. The filing triggers a $5 million payment to Columbia from partner Watson Pharmaceuticals Inc. (NYSE:WPI).

Corcept Therapeutics Inc. (NASDAQ:CORT) lost $0.71 (15%) to $3.91 last week after FDA accepted for review an NDA for Corlux mifepristone to treat Cushing's syndrome. The PDUFA date is Feb. 17, 2012. Corcept had originally requested Priority Review, which could have meant an FDA action date as early as October...